Identification of novel survivin-derived CTL epitopes

Related Experiment Video

Updated: Aug 29, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Sine Reker1, Anders Meier, Lars Holten-Andersen

  • 1Tumor Immunology Group, Division of Canter Biology, Danish Cancer Society, Copenhagen, Denmark.

Cancer Biology & Therapy
|January 17, 2004
PubMed

Insights

Scientists identified new survivin epitopes for cancer immunotherapy. These targets, recognized by cytotoxic lymphocytes (CTLs), expand patient eligibility for survivin peptide-based treatments and reduce immune escape risks.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Tumor antigens are crucial for cancer cell survival and represent therapeutic targets.
  • Immunoselection can lead to antigen loss variants, particularly during immunotherapy.
  • Survivin is an inhibitor of apoptosis protein and a potential tumor antigen.

Purpose of the Study:

  • To identify novel survivin-derived epitopes restricted by various HLA alleles (HLA-A1, HLA-A2, HLA-A3, HLA-A11).
  • To characterize spontaneous cytotoxic lymphocyte (CTL) responses against these novel epitopes in cancer patients.
  • To expand patient eligibility for survivin-based peptide immunotherapy and mitigate immune escape.

Main Methods:

  • Characterization of novel HLA-restricted survivin epitopes.
  • Analysis of spontaneous CTL responses in cancer patients.
  • Assessment of epitope targeting across multiple HLA restriction elements.

Main Results:

  • Identification and characterization of novel HLA-A1, HLA-A2, HLA-A3, and HLA-A11-restricted survivin epitopes.
  • Demonstration of spontaneous CTL responses against these survivin epitopes in cancer patients.
  • Increased patient eligibility for survivin peptide-based immunotherapy.

Conclusions:

  • Novel survivin epitopes broaden the scope of survivin-based cancer immunotherapy.
  • Targeting multiple HLA-restricted survivin epitopes enhances therapeutic potential.
  • This strategy may reduce the risk of immune escape through HLA-allele loss.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...